Together, these data indicate a role for tumour-associated isoform switching to IQSEC1 v2 to promote PI3K-AKT signalling and metastasis across cancer types, resulting in treatment resistance and a robust decrease in patient survival. This evidence concerns the gene AKT1 and neoplasm.